Merck Serono to provide free Pliazon cream to mCRC patients
Drug manufacturer Merck Serono has announced that it will provide its Pliazon cream for skin reactions to all UK patients undergoing anti-EGFR antibody treatment for metastatic colorectal cancer (mCRC).
Pliazon® is a regenerating, moisturising and normalising cream that forms a protective barrier on the skin which shields the skin from external factors that may cause damage. The treatment is available via an order form that is available by emailing CSC.uk@merckserono.net
Please note You must be a registered user of Chemist+Druggist and logged in to add comments. Opinions expressed here are those of the writers and do not necessarily reflect those of Chemist+Druggist. Comments are considered in the public domain and may be used in future Chemist+Druggist coverage. We accept no responsibility, legal or otherwise, for the accuracy or the content of member comments. However, any comments deemed to be libellous will be removed
